Ημερολόγιο Συνεδρίων για το HIV/AIDS

February 2020
5th Viruses 2020 - Novel Concepts in Virology Barcelona, Spain
8th 2nd International Conference on Social Sciences, Humanities, Business Management & Economics Research (SHME) Paris, France
10th International Conference on HIV/AIDS 2020 Venice, Italy
13th LISD International World Research Congress on Health Sciences (IWRCHS) 2020, London London, United Kingdom
24th Healthcare Technologies and Public Health 2020 Lisbon, Portugal
26th International Conference on HIV/AIDS Prevention and Control Pretoria, South Africa
27th International Conference on Entrepreneurship, Business, Economics and Management Research MalΓ©, Maldives
27th ISBER International Conference on Teaching and Learning, Business Ethics, Management, Social Sciences & Humanities MalΓ©, Maldives
29th International Conference on African Studies Pretoria, South Africa
April 2020
16th American Conference for the Treatment of HIV Chicago, United States of America
May 2020
16th International Conference on Infectious Diseases Colombo, Sri Lanka
18th 03rd International Conference on Pharmaceutical Sciences Colombo, Sri Lanka
21st World Congress on Control and Prevention of HIV/AIDS Osaka, Japan
24th 02nd International Conference on Community Medicine and Public Health Colombo, Sri Lanka
25th 03rd International Conference on Non Communicable Diseases Colombo, Sri Lanka
28th HIV Update: Contemporary Issues in Management Boston, United States of America
August 2020
15th 3rd International Conference on Marketing Finance, HR and Social Science Barcelona, Spain
October 2020
19th 2nd World Nursing and Health Care Congress San Francisco, United States of America
November 2020
28th 3rd International Conference on Research Methodology for Business Economics, Social Sciences and Entrepreneurial Studies Bali, Indonesia
December 2020
1st 6th Global Public Health 2020 Bali, Indonesia
16th 03rd International Conference on Women and Child Health Colombo, Sri Lanka
18th 06th International Conference on Ayurveda Traditional Medicine and Medicinal Plants Colombo, Sri Lanka
1


Variability of CD4+ cell counts in HIV-1 uninfected volunteers who are eligible for a Phase I HIV vaccine study

Fri, 24 Jan 2020 00:00:00 GMT-06:00 - Stafford, Kristen A.; Mayer, Bryan T.; Fulp, William; Chua, Joel; Davis, Charles; Gilliam, Bruce; Dong, Dan; Gallo, Robert C.; Sajadi, Mohammad M.
Θέμα: Vaccines and biologics containing CD4 molecules or HIV gp120 might induce antibodies targeting CD4. We evaluated temporal variability of CD4 levels in healthy volunteers to quantify declines that could indicate true adverse events. Design: Prospective observational cohort study of 100 healthy adults without HIV infection from the Baltimore region.
Μέθοδοι: Participants enrolled and consented to blood draws for immunologic lab panels performed once every eight weeks for 48 weeks. The primary CD4+ measurements were CD4+ absolute count (cells/mm3) and CD4 percentage (CD4%, total CD4 cells/total lymphocyte cells). CD4 changes over time were modeled using fold-changes for CD4+ absolute counts and differences for CD4 percentages.
Αποτελέσματα: Variation of average CD4+ cell counts and percentages were highly participant-specific (p < 0.001 for both). However, changes in both CD4+ measurements over time were stable in the population. We proposed thresholds to flag unusual drops using 1.5 standard deviation estimates, calculated as 1.5-fold declines for CD4+ count 6.4% declines for CD4 percentage. In this healthy cohort, flagging simultaneous declines in both measurements corresponded to a low false-positive rate (5.26%).
Συμπεράσματα: Normal biological variation in large lymphocytes should be taken into account to establish thresholds for adverse changes in clinical trials. The inherent subject-specific variability in CD4 levels make establishing absolute cutoffs difficult. However, this study proposes that thresholds for declines using 1.5 standard deviations from these data (50% in absolute count and 6.4% for CD4 percentage) allow a small false-positive rate (∼5%) that could maintain sensitivity for true adverse events in a clinical trial. Corresponding author: Mohammad M. Sajadi, MD, Institute of Human Virology, University of Maryland School of Medicine, 725 W. Lombard Street, Baltimore, Maryland 21201, msajadi@ihv.umaryland.edu The authors report no conflicts of interest related to this work. * These authors contributed equally to this manuscript Funding: This study was funded by the Bill and Melinda Gates Foundation. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. - Β© 2020

About us

Στο hivaids.gr, φιλοξενούμε αφιλοκερδώς το "Πρόγραμμα Συνεργασίας" Μονάδων Λοιμώξεων για την ανάπτυξη διαδικτυακής τράπεζας κλινικών παραμέτρων. Το Πρόγραμμα δημιουργήθηκε από έναν γιατρό ειδικό στην HIV λοίμωξη με τη συμμετοχή των Μονάδων: Περισσότερα

% Αναπηρία και HIV

Νέος κανονισμός

Ενιαίος Πίνακας Προσδιορισμού Ποσοστού Αναπηρίας

Ημερολόγιο

@ Διαύγεια

ΔιαύγειαΔι@ύγεια

διαφάνεια στο κράτος

Διαδικτυακές αναρτήσεις διοικητικών αποφάσεων για το HIV/AIDS

Έρευνα

Σας έχει σπάσει ποτέ το προφυλακτικό κατά τη διάρκεια μιας ερωτικής επαφής;
Ναι
Όχι
Δεν χρησιμοποιώ

Επικοινωνία

Newsletter

Ανακοινώσεις

Χρήσιμες πληροφορίες